AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11575415
Drug: Double injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double injection divided between median and radial nerves (group 2)
Trial: 2254515
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral treatment targeting child and parent behavior
Trial: 2254515
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral treatment
Trial: 6929102
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline infused i.v. during the operation and daily for 4 days postoperatively
Trial: 6929102
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline infused i.v. during the operation, plus 200 mg instilled into the peritoneal cavity at the completion of the operation
Trial: 31274211
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg vitamin D3
Trial: 26070652
Drug: Half-dose L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Half-dose L-T4 treatment for 5 weeks (HD group)
Trial: 26070652
Drug: Conventional L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional L-T4 withdrawal (TW group)
Trial: 26070652
Drug: Half-dose L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Half-dose L-T4 treatment (HD group)
Trial: 25002722
Drug: Weekly topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly topotecan 4 mg/m² IV with ziv-aflibercept 6 mg/kg IV every 21 days
Trial: 25002722
Drug: Weekly topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly topotecan 4 mg/m² IV
Trial: 22332815
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only oral and written instructions on Kegel exercises after catheter removal.
Trial: 19295468
Drug: Diaphragm/gel provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm/gel provision
Trial: 17713339
Drug: Individually designed
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually designed patient-centered preventive program including counseling, toothbrushes, fluoride toothpaste, fluoride and xylitol lozenges, and fluoride/chlorhexidine varnish applications.
Trial: 11448848
Drug: Water immersion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water immersion (WI) with sustained angiotensin-converting enzyme inhibitor therapy in HF patients
Trial: 375408
Drug: Levamisole at
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole at 3 mg/kg daily for 8 days
Trial: 375408
Drug: Mebendazole at
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole at 6 mg/kg daily for 10 days following 8 days of levamisole
Trial: 375408
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) at 6 mg/kg daily for 12 days
Trial: 11176742
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy for patients with high-normal BLB
Trial: 7535192
Drug: Drugs inhibiting
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs inhibiting nitric oxide (NO)
Trial: 3377974
Drug: Monochloroacetic acid
RxNorm normalized name: MONOCHLOROACETIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochloroacetic acid crystals and 60% salicylic acid ointment
Trial: 28059619
Drug: Oral rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rotavirus vaccine (RV) before injection
Trial: 28059619
Drug: Oral rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rotavirus vaccine (RV) after injection
Trial: 15320956
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram daily
Trial: 15320956
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg citalopram daily
Trial: 15320956
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram after 8 weeks
Trial: 11055323
Drug: 3-acetyl-7-oxo-DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-acetyl-7-oxo-DHEA (50 mg/d for 7 days, 100 mg/d for 7 days, 200 mg/d for 28 days)
Trial: 11055323
Drug: 3-acetyl-7-oxo-DHEA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-acetyl-7-oxo-DHEA (200 mg/d for 28 days)
Trial: 11354235
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sertraline
Trial: 11282810
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of paroxetine
Trial: 8302414
Drug: CSA liquid
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSA liquid (mean dose 312 mg/day)
Trial: 8302414
Drug: CSA capsules
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSA capsules (mean dose 312 mg/day)
Trial: 8302414
Drug: CSA capsules
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSA capsules
Trial: 3532669
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy with dietary advice
Trial: 30541041
Drug: Intra-articular corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular corticosteroid (triamcinolone 20 mg)
Trial: 27118785
Drug: Laninamivir octanoate
RxNorm normalized name: Laninamivir octanoate
DrugBank: Laninamivir octanoate (DB11888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laninamivir octanoate 40 mg single administration (LO‐40SD)
Trial: 27118785
Drug: Laninamivir octanoate
RxNorm normalized name: Laninamivir octanoate
DrugBank: Laninamivir octanoate (DB11888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laninamivir octanoate 20 mg once daily for 2 days (LO‐20TD)
Trial: 22513048
Drug: ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (8 mg/d; group O, n=10)
Trial: 22513048
Drug: metoclopramide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide (30 mg/d; group M, n=10)
Trial: 20381932
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (8 sessions, 60 min each over 8 weeks)
Trial: 15572587
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HiDAC) alone, 3 courses
Trial: 15572587
Drug: Multiagent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent chemotherapy regimen (1 course of HiDAC, 1 course with etoposide and cyclophosphamide, 1 course with diaziquone and mitoxantrone)
Trial: 15572587
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (HiDAC and multiagent chemotherapy)
Trial: 22920577
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment (intramuscularly)
Trial: 21060024
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy followed by surgery
Trial: 16182827
Drug: Tacrolimus (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (initial oral dose 0.2 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (4 mg/kg for 4 days)
Trial: 16182827
Drug: Cyclosporine‐microemulsion (ME)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine‐microemulsion (ME) (initial daily oral dose 7 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (1.25 mg/kg for 4 days)
Trial: 12559940
Drug: Inogatran (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (a direct thrombin inhibitor)
Trial: 12559940
Drug: High fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fibrinogen level (pre-treatment top tertile)
Trial: 29255272
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg every other day, once a morning
Trial: 23701115
Drug: Spontaneous ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous ventilation (SV) using dexmedetomidine (4 μg∙kg(‐1)) and topical lidocaine (3‐5 mg∙kg(‐1))
Trial: 23701115
Drug: Manual jet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual jet ventilation (MJV) with fentanyl (2 μg∙kg(‐1)), propofol (3‐5 mg∙kg(‐1)), and succinylcholine (1 mg∙kg(‐1))
Trial: 19214115
Drug: Diaphragm +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm + gel + condoms
Trial: 11436970
Drug: Pharmacotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy plus immunotherapy (IT) in tablets
Trial: 25894106
Drug: Pharmacotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy alone (Control)
Trial: 8290411
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg) + Amiloride (2.5 mg)
Trial: 8290411
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg) + Triamterene (50 mg)
Trial: 30550209
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with nasal corticosteroids (budesonide) and nasal antihistamine (azelastine) for 8 weeks
Trial: 27138024
Drug: Aclidinium bromide/formoterol
RxNorm normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) 400/12 μg
Trial: 27138024
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate 12 μg
Trial: 25137221
Drug: 30 min/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min/day walking prescription
Trial: 25137221
Drug: 60 min/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 min/day walking prescription
Trial: 25137221
Drug: 90 min/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 min/day walking prescription
Trial: 1602034
Drug: Metronidazole, 250
RxNorm normalized name: MetroNIDAZOLE, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole, 250 mg 3 x a day for 1 week
Trial: 3912193
Drug: Cyclacillin with
RxNorm normalized name: cyclacillin
DrugBank: Cyclacillin (DB01000)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclacillin with Amoxicillin
Trial: 20472815
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (mean treatment duration of 25.6 months)
Trial: 12915698
Drug: Buformine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buformine treatment (n=10)
Trial: 10591092
Drug: Preoperative diuretics
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative diuretics
Trial: 8713688
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg) +/− Indapamide (2.5 mg)
Trial: 30804274
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids for 6 months
Trial: 29069003
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 250 mL 20% mannitol and 1 L 0.9% saline orally at 05:00 hours on the day of the procedure.
Trial: 29069003
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Same preparation as Group A, taken at 20:00 on the day before, and at 05:00 on the day of CE; in addition, 20 mL oral simethicone taken 30 minutes before CE.
Trial: 29069003
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Identical to Group B, except patients fasted for 3 days and took 3 g senna orally 3 times daily before CE.
Trial: 17062760
Drug: Single-dose bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose bexarotene (400 mg/m2)
Trial: 15313870
Drug: Pollen blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pollen blocker cream applied 4 times daily for 9 days
Trial: 15313870
Drug: Carboxymethylcellulose in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose in gel (placebo) applied 4 times daily for 9 days
Trial: 11181682
Drug: Oral docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral docetaxel 75 mg/m(2) with CsA 15 mg/kg
Trial: 11181682
Drug: Oral docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral docetaxel 75 mg/m(2) without CsA
Trial: 11181682
Drug: Intravenous docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous docetaxel 100 mg/m(2)
Trial: 9037321
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor treatment (fosinopril)
Trial: 8316680
Drug: Thioridazine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 1.25 mg/kg/day
Trial: 8316680
Drug: Thioridazine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 2.5 mg/kg/day
Trial: 3528988
Drug: Morphine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (n = 9)
Trial: 31612329
Drug: Preoperative neoadjuvant
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative neoadjuvant chemotherapy
Trial: 31612329
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of immune checkpoint inhibitors to cytotoxic chemotherapy
Trial: 18688284
Drug: AEB071 (PKC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEB071 (PKC inhibitor), administered as single and multiple ascending oral doses to patients with psoriasis.
Trial: 18688284
Drug: AEB071 (PKC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEB071 (PKC inhibitor), administered as single doses to healthy volunteers.
Trial: 18688284
Drug: AEB071 (PKC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEB071 (PKC inhibitor), administered to patients with psoriasis.
Trial: 12872392
Drug: Fuzheng Yiliu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Yiliu Granule (FYG) in addition to conventional chemotherapy
Trial: 10344610
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Trial: 10344610
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Trial: 1722769
Drug: Bleomycin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin treatment (15 mg by continuous infusion two times a week during 5 weeks)
Trial: 1722769
Drug: Classical radiation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical radiation treatment with telecobalt‐therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron)
Trial: 31854054
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group (individualized nutritional treatment)
Trial: 21605175
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of betamethasone valerate 0.1% corticosteroid cream
Trial: 21605175
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of betamethasone valerate 0.1% corticosteroid cream
Trial: 21605175
Drug: Urea-containing moisturizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea-containing moisturizer (substituted for corticosteroid cream in the morning)
Trial: 19016342
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BH(4)/kg body weight
Trial: 19016342
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BH(4)/kg body weight
Trial: 19016342
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg BH(4)/kg body weight
Trial: 15028243
Drug: [(11)C]L‐deprenyl (DEP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(11)C]L‐deprenyl (DEP)
Trial: 11597936
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy (niacin 2.5 g/d, lovastatin 40 mg/d, colestipol 20 g/d) for 10 years
Trial: 2586436
Drug: OK-432 intratumoral
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: OK-432 intratumoral injection (group A)
Trial: 195411
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (COMB)
Trial: 195411
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (BACO)
Trial: 16414235
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² and Docetaxel 35 mg/m²
Trial: 3718600
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (DPH) preparations A (tablet) and B (buffered solution) containing 50 mg DPH-HCl
Trial: 3718600
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation C containing 31 mg DPH-HCl and 23 mg 8-chlorotheophylline
Trial: 3718600
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with 8-chlorotheophylline
Trial: 2431015
Drug: Lindane 1%
RxNorm normalized name: LINDANE 1% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindane 1% lotion
Trial: 21597409
Drug: Piracetam 12
RxNorm normalized name: piracetam 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 12 g
Trial: 9129038
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cytosine arabinoside and daunomycin + rhG‐CSF
Trial: 7948961
Drug: C2T (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2T (2 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Trial: 7948961
Drug: C1T (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1T (1 g ceftazidime every 8 h plus 5 mg/kg/day tobramycin)
Trial: 3361022
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg/kg/day during the first 3 days
Trial: 31915047
Drug: Direct oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Direct oxytocin injection
Trial: 11898510
Drug: Triptans (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptans (specific dosage and duration not mentioned)
Trial: 8037261
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium lactate infusion
Trial: 23030252
Drug: Pilocarpine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (10 mg)
Trial: 19216936
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg, i.e., two sticks of Stay Alert gum) administered at 0100, 0300, 0500, and 0700 during nights 2, 3, and 4
Trial: 19216936
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the same times as caffeine
Trial: 11881131
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg once-daily for four weeks, titrated to 80 mg if necessary
Trial: 11881131
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg once-daily for four weeks, titrated to 20 mg if necessary
Trial: 9663917
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy (n=16)
Trial: 2687135
Drug: Proteolytic enzymes
RxNorm normalized name: Proteolytic enzymes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proteolytic enzymes administered endotracheally in pre- and postoperative periods